What it's for (Indications)
- Dorzolamide is a topical carbonic anhydrase inhibitor primarily indicated for the reduction of elevated intraocular pressure (IOP) in patients diagnosed with open-angle glaucoma or ocular hypertension.
- It can be utilized as monotherapy in patients who are intolerant to or insufficiently responsive to beta-blockers, or as adjunctive therapy in combination with ophthalmic beta-blockers or prostaglandin analogs to achieve additional IOP reduction.
- Its efficacy stems from its ability to decrease aqueous humor production within the eye, thereby lowering pressure and mitigating the risk of optic nerve damage and subsequent vision loss associated with these chronic ocular conditions.
- This therapeutic agent offers a valuable option for managing complex glaucoma cases and achieving target IOPs.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | When used as monotherapy, the recommended dosage of dorzolamide ophthalmic solution 2% is one drop instilled into the conjunctival sac of the affected eye(s) three times daily (TID). In instances where dorzolamide is employed as adjunctive therapy alongside an ophthalmic beta-adrenergic blocking agent, the suggested dosage is typically reduced to one drop in the affected eye(s) two times daily (BID). It is crucial for patients to strictly adhere to the prescribed dosing regimen and administration technique to maximize therapeutic efficacy and minimize potential side effects. Patients should be instructed to avoid touching the dropper tip to the eye or any other surface to prevent contamination of the solution. Any deviation from the prescribed dosage or regimen should only occur under the direct guidance of a qualified healthcare professional. |
Safety & Warnings
Common Side Effects
- The most frequently reported ocular adverse reactions associated with dorzolamide ophthalmic solution include transient stinging or burning of the eye immediately following instillation, bitter taste, superficial punctate keratitis, conjunctivitis, blurred vision, ocular itching, and lid reactions.
- Less common but notable ocular effects may include tearing, dryness, photophobia, and transient corneal edema.
- Systemic adverse effects, while generally less frequent due to limited systemic absorption, can include headache, nausea, asthenia/fatigue, and, in rare instances, dizziness or paresthesia.
- Due to its sulfonamide chemical structure, there is also a potential for systemic sulfonamide-like allergic reactions, which can be severe.
- Patients should be advised to promptly report any severe, persistent, or unusual side effects to their ophthalmologist or healthcare provider.
Serious Warnings
- Black Box Warning: Dorzolamide ophthalmic solution (Trusopt) does not carry an official FDA-mandated Black Box Warning. However, due to its chemical classification as a sulfonamide, it is imperative to include a 'Serious Warnings' section that highlights potential severe risks associated with its use. As with other sulfonamide derivatives, dorzolamide can be systemically absorbed following topical ocular administration, leading to adverse reactions characteristic of systemic sulfonamides. These reactions, though rare with ophthalmic use, can be severe and potentially life-threatening. They include, but are not limited to, Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias. Patients should be thoroughly counseled on the remote possibility of such reactions and advised to discontinue the medication and seek immediate medical attention if any signs or symptoms suggestive of severe hypersensitivity or systemic toxicity occur, such as a rash, fever, or unusual bruising/bleeding. Close monitoring for these serious adverse events is recommended, especially in patients with a history of sulfonamide sensitivity.
- Patients receiving dorzolamide should be aware of several important warnings.
- As dorzolamide is a sulfonamide, it carries the potential for sulfonamide-like adverse reactions, which can include severe systemic reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, and aplastic anemia.
- Although topical administration minimizes systemic exposure, patients should be advised to discontinue the medication and seek immediate medical attention if signs of severe hypersensitivity or unusual dermatologic reactions develop.
- Caution is also advised in patients with pre-existing corneal conditions, particularly those with low endothelial cell counts, due to the drug's potential to exacerbate corneal edema or decompensation.
- The safety and efficacy of dorzolamide have not been established in patients with acute angle-closure glaucoma.
- Patients should remove contact lenses prior to instillation and wait at least 15 minutes before reinserting them.
- Concomitant use of oral carbonic anhydrase inhibitors is not recommended due to the potential for additive systemic effects.
How it Works (Mechanism of Action)
Dorzolamide is a highly specific and potent reversible inhibitor of carbonic anhydrase, an enzyme found in various tissues throughout the body, including the ciliary body of the eye. Within the ciliary body, carbonic anhydrase plays a critical role in the production of aqueous humor by catalyzing the reversible reaction involving the hydration of carbon dioxide and dehydration of carbonic acid. This process generates bicarbonate ions, which are subsequently secreted into the posterior chamber, driving sodium and fluid transport and ultimately leading to aqueous humor formation. By inhibiting this enzyme, dorzolamide effectively reduces the formation of bicarbonate ions, thereby decreasing the rate of aqueous humor secretion. The net pharmacological effect is a significant reduction in intraocular pressure, which is beneficial in the management of glaucoma and ocular hypertension.
Commercial Brands (Alternatives)
No other brands found for this formula.